# US 9,920,122 B2 · Compositions and methods to enhance the immune system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,920,122 B2
- Document ID: US9920122B2
- Status: Granted
- Kind: B2
- Application number: 15/145,365
- Filed: 2016-05-03
- Published: 2016-08-25
- Granted: 2018-03-20
- Earliest claimed: 2008-04-23
- Assignees: Stichting Sanquin Bloedvoorziening
- Applicants: Stichting Sanquin Bloedvoorziening
- Inventors: Timo Kars van den Berg
- Web page: https://patentgrep.com/patent/US9920122B2

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 39/12: Viral antigens
- A61K 39/275: Poxviridae, e.g. avipoxvirus
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 35/00: Antineoplastic agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2887: {against CD20}
- C07K 16/2893: {against CD52}
- C07K 16/30: from tumour cells
- C07K 16/32: against translation products of oncogenes
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/572: {cytotoxic response}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77: Internalization into the cell
- C12N 2710/24034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.

## Claims

### Claim 1

A composition comprising
(i) a therapeutic compound that can trigger a host's immune effector cells against a cancer cell, wherein said therapeutic compound is a therapeutic antibody comprising a human or non-human primate IgG Fc portion, wherein the therapeutic antibody induces antibody-dependent cellular cytotoxicity (ADCC), and
(ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPα, wherein said agent is an anti-SIRPα antibody or a Fab fragment, a F(ab′)2 fragment or a scFv fragment thereof.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the cancer cell is a non-Hodgkin's lymphoma cell, a breast cancer cell, a chronic lymphocytic leukemia cell or a colorectal cancer cell.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein the therapeutic antibody is selected from the group consisting of rituximab, trastuzumab, alemtuzumab, cetuximab, and panitumumab.

### Claim 4 (depends on 3)

The composition according to claim 3, wherein the cancer cell is a non-Hodgkin's lymphoma cell, a breast cancer cell, a chronic lymphocytic leukemia cell, or a colorectal cancer cell.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the cancer cell is a non-Hodgkin's lymphoma cell or a chronic lymphocytic leukemia cell.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the cancer cell is a breast cancer cell.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein the cancer cell is a colorectal cancer cell.

### Claim 8 (depends on 1)

The composition according to claim 1, wherein the therapeutic antibody comprises a human IgG1 Fc portion or a human IgG3 Fc portion.

### Claim 9

A composition comprising
(i) a therapeutic antibody selected from the group consisting of rituximab, trastuzumab, alemtuzumab, bevacizumab, cetuximab, and panitumumab, and
(ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPα, wherein said agent is an anti-SIRPα antibody or a Fab fragment, a F(ab′)2 fragment or a scFv fragment thereof.

### Claim 10 (depends on 9)

The composition according to claim 9, wherein the therapeutic antibody is rituximab.

### Claim 11 (depends on 10)

The composition according to claim 10, wherein the cancer cell is a non-Hodgkin's lymphoma cell or a chronic lymphocytic leukemia cell.

### Claim 12 (depends on 9)

The composition according to claim 9, wherein the therapeutic antibody is trastuzumab.

### Claim 13 (depends on 12)

The composition according to claim 12, wherein the cancer cell is a breast cancer cell.

### Claim 14 (depends on 9)

The composition according to claim 9, wherein the therapeutic antibody is alemtuzumab.

### Claim 15 (depends on 14)

The composition according to claim 14, wherein the cancer cell is a chronic lymphocytic leukemia cell.

### Claim 16 (depends on 9)

The composition of claim 9, wherein the therapeutic antibody is cetuximab.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the cancer cell is a colorectal cancer cell.